市場調査レポート
商品コード
1008920

抗炎症治療の世界市場:2021年~2025年

Global Anti-inflammatory Therapeutics Market 2021-2025

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.14円
抗炎症治療の世界市場:2021年~2025年
出版日: 2021年05月11日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の抗炎症治療の市場規模は、2021年から2025年の間に327億米ドル成長し、予測期間中は6%のCAGRで成長する見込みです。

同市場は、免疫介在性炎症性疾患(IMID)の有病率の増加、標的療法の利用可能性によって牽引されています。

当レポートでは抗炎症治療の世界市場の全体的な分析、市場規模と予測、動向、成長要因、課題、および約25のベンダーをカバーする分析を提供しています。

目次

  • エグゼクティブサマリー
  • 市場概要
  • 市場情勢
    • 市場エコシステム
    • バリューチェーン分析
  • 市場サイジング
    • 市場の定義
    • 市場セグメント分析
    • 2020年の市場規模
    • 市場見通し:2020~2025年の見通し
  • ファイブフォース分析
    • ファイブフォースまとめ
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争の脅威
    • 市況

    市場セグメンテーション:アプリケーション別

    • 市場セグメント
    • アプリケーション別比較
    • 関節リウマチ(RA):市場規模と予測(2020年~2025年)
    • 乾癬:市場規模と予測(2020年~2025年)
    • 多発性硬化症 (MS) :市場規模と予測(2020年~2025年)
    • アプリケーション別の市場機会
  • 市場セグメンテーション:医薬品クラス別
    • 市場セグメント
    • 医薬品クラス別比較
    • 抗炎症バイオ医薬品:市場規模と予測(2020年~2025年)
    • コルチコステロイド:市場規模と予測(2020年~2025年)
    • NSAID:市場規模と予測(2020年~2025年)
    • 医薬品クラス別の市場機会
  • 顧客情勢
  • 地域別情勢
    • 地域別セグメンテーション
    • 地域別比較
    • 北米:市場規模と予測(2020年~2025年)
    • 欧州:市場規模と予測(2020年~2025年)
    • アジア:市場規模と予測(2020年~2025年)
    • その他の地域:市場規模と予測(2020年~2025年)
    • 主要国
    • 地域の市場機会
    • 市場の推進力
    • 市場の課題
    • 市場動向
  • ベンダー情勢
    • ベンダー情勢
    • ベンダー情勢
    • 創造的破壊の状況
  • ベンダー分析
    • 対象ベンダー
    • ベンダーの市場ポジショニング
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Bayer AG
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Johnson and Johnson
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
  • 付録
    • 調査範囲
    • 米ドルの通貨換算レート
    • 調査手法
    • 略語一覧
目次
Product Code: IRTNTR41324

Technavio has been monitoring the anti-inflammatory therapeutics market and it is poised to grow by $ 32.70 bn during 2021-2025, progressing at a CAGR of over 6% during the forecast period. Our report on anti-inflammatory therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in prevalence of IMID and availability of targeted therapy. In addition, increase in prevalence of IMID is anticipated to boost the growth of the market as well.

The anti-inflammatory therapeutics market analysis includes application segment and geographic landscape.

Technavio's anti-inflammatory therapeutics market is segmented as below:

By Application

  • RA
  • Psoriasis
  • MS

By Geography

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increase in off-label use as one of the prime reasons driving the anti-inflammatory therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on anti-inflammatory therapeutics market covers the following areas:

  • Anti-inflammatory therapeutics market sizing
  • Anti-inflammatory therapeutics market forecast
  • Anti-inflammatory therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-inflammatory therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, and Pfizer Inc. Also, the anti-inflammatory therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
  • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Application
    • Market segments
    • Comparison by Application
    • RA - Market size and forecast 2020-2025
    • Psoriasis - Market size and forecast 2020-2025
    • MS - Market size and forecast 2020-2025
    • Market opportunity by Application
  • Market Segmentation by Drug Class
    • Market segments
    • Comparison by Drug Class
    • Anti-inflammatory biologicals - Market size and forecast 2020-2025
    • Corticosteroids - Market size and forecast 2020-2025
    • NSAIDs - Market size and forecast 2020-2025
    • Market opportunity by Drug Class
  • Customer Landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Bayer AG
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Johnson and Johnson
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Key Finding 9
  • 9: Parent market
  • 10: Market characteristics
  • 11: Offerings of vendors included in the market definition
  • 12: Market segments
  • 13: Global - Market size and forecast 2020 - 2025 ($ billion)
  • 14: Global market: Year-over-year growth 2020 - 2025 (%)
  • 15: Five forces analysis 2020 & 2025
  • 16: Bargaining power of buyers
  • 17: Bargaining power of suppliers
  • 18: Threat of new entrants
  • 19: Threat of substitutes
  • 20: Threat of rivalry
  • 21: Market condition - Five forces 2020
  • 22: Application - Market share 2020-2025 (%)
  • 23: Comparison by Application
  • 24: RA - Market size and forecast 2020-2025 ($ billion)
  • 25: RA - Year-over-year growth 2020-2025 (%)
  • 26: Psoriasis - Market size and forecast 2020-2025 ($ billion)
  • 27: Psoriasis - Year-over-year growth 2020-2025 (%)
  • 28: MS - Market size and forecast 2020-2025 ($ billion)
  • 29: MS - Year-over-year growth 2020-2025 (%)
  • 30: Market opportunity by Application
  • 31: Other1 - Market share 2020-2025 (%)
  • 32: Comparison by Other1
  • 33: Anti-inflammatory biologicals - Market size and forecast 2020-2025 ($ billion)
  • 34: Anti-inflammatory biologicals - Year-over-year growth 2020-2025 (%)
  • 35: Corticosteroids - Market size and forecast 2020-2025 ($ billion)
  • 36: Corticosteroids - Year-over-year growth 2020-2025 (%)
  • 37: NSAIDs - Market size and forecast 2020-2025 ($ billion)
  • 38: NSAIDs - Year-over-year growth 2020-2025 (%)
  • 39: Market opportunity by Other1
  • 40: Customer landscape
  • 41: Market share by geography 2020-2025 (%)
  • 42: Geographic comparison
  • 43: North America - Market size and forecast 2020-2025 ($ billion)
  • 44: North America - Year-over-year growth 2020-2025 (%)
  • 45: Europe - Market size and forecast 2020-2025 ($ billion)
  • 46: Europe - Year-over-year growth 2020-2025 (%)
  • 47: Asia - Market size and forecast 2020-2025 ($ billion)
  • 48: Asia - Year-over-year growth 2020-2025 (%)
  • 49: ROW - Market size and forecast 2020-2025 ($ billion)
  • 50: ROW - Year-over-year growth 2020-2025 (%)
  • 51: Key leading countries
  • 52: Market opportunity by geography ($ billion)
  • 53: Impact of drivers and challenges
  • 54: Vendor landscape
  • 55: Landscape disruption
  • 56: Industry risks
  • 57: Vendors covered
  • 58: Market positioning of vendors
  • 59: AbbVie Inc. - Overview
  • 60: AbbVie Inc. - Product and service
  • 61: AbbVie Inc. - Key offerings
  • 62: AbbVie Inc. - Key customers
  • 63: AbbVie Inc. - Segment focus
  • 64: Amgen Inc. - Overview
  • 65: Amgen Inc. - Business segments
  • 66: Amgen Inc. - Key offerings
  • 67: Amgen Inc. - Key customers
  • 68: Amgen Inc. - Segment focus
  • 69: AstraZeneca Plc - Overview
  • 70: AstraZeneca Plc - Product and service
  • 71: AstraZeneca Plc - Key offerings
  • 72: AstraZeneca Plc - Key customers
  • 73: AstraZeneca Plc - Segment focus
  • 74: Bayer AG - Overview
  • 75: Bayer AG - Business segments
  • 76: Bayer AG - Key offerings
  • 77: Bayer AG - Key customers
  • 78: Bayer AG - Segment focus
  • 79: F. Hoffmann-La Roche Ltd. - Overview
  • 80: F. Hoffmann-La Roche Ltd. - Business segments
  • 81: F. Hoffmann-La Roche Ltd. - Key offerings
  • 82: F. Hoffmann-La Roche Ltd. - Key customers
  • 83: F. Hoffmann-La Roche Ltd. - Segment focus
  • 84: GlaxoSmithKline Plc - Overview
  • 85: GlaxoSmithKline Plc - Business segments
  • 86: GlaxoSmithKline Plc - Key offerings
  • 87: GlaxoSmithKline Plc - Key customers
  • 88: GlaxoSmithKline Plc - Segment focus
  • 89: Johnson and Johnson - Overview
  • 90: Johnson and Johnson - Business segments
  • 91: Johnson and Johnson - Key offerings
  • 92: Johnson and Johnson - Key customers
  • 93: Johnson and Johnson - Segment focus
  • 94: Merck and Co. Inc. - Overview
  • 95: Merck and Co. Inc. - Business segments
  • 96: Merck and Co. Inc. - Key offerings
  • 97: Merck and Co. Inc. - Key customers
  • 98: Merck and Co. Inc. - Segment focus
  • 99: Novartis AG - Overview
  • 100: Novartis AG - Business segments
  • 101: Novartis AG - Key offerings
  • 102: Novartis AG - Key customers
  • 103: Novartis AG - Segment focus
  • 104: Pfizer Inc. - Overview
  • 105: Pfizer Inc. - Business segments
  • 106: Pfizer Inc. - Key offerings
  • 107: Pfizer Inc. - Key customers
  • 108: Pfizer Inc. - Segment focus
  • 109: Currency conversion rates for US$
  • 110: Research Methodology
  • 111: Validation techniques employed for market sizing
  • 112: Information sources
  • 113: List of abbreviations